Evidence map›Paper›PMID 41367679›Full record

ArticleRSC advances2025

Hydrophobic alkyl-linked base-modified pyrimidine and 7-deazapurine 2'-deoxyribonucleoside phosphoramidites: synthesis and application in solid-phase synthesis of modified and hypermodified oligonucleotides.

Ivana Jestřábová, Lucie Bednárová, Lenka Poštová Slavětínská, Michal Hocek

Abstract read
In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ivana JestřábováInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences Flemingovo nam. 2 CZ-16000 Prague 6 Czech Republic hocek@uochb.cas.cz.
Lucie BednárováInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences Flemingovo nam. 2 CZ-16000 Prague 6 Czech Republic hocek@uochb.cas.cz.
Lenka Poštová SlavětínskáInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences Flemingovo nam. 2 CZ-16000 Prague 6 Czech Republic hocek@uochb.cas.cz.
Michal HocekInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences Flemingovo nam. 2 CZ-16000 Prague 6 Czech Republic hocek@uochb.cas.cz.ORCID https://orcid.org/0000-0002-1113-2047

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of 2'-deoxyribonucleoside 3'-phosphoramidites bearing hydrophobic alkyl-linked modifications at nucleobases was synthesized, namely 5-phenylethyluracil, 5-pentylcytosine, 7-(indol-3-yl)ethyl-7-deazaadenine, and 7-isopentyl-7-deazaguanine derivatives. These nucleoside phosphoramidites were used for solid-phase synthesis of modified and hypermodified oligonucleotides containing up to fifteen modified nucleotides in a row. Their hybridization with complementary non-modified or modified oligonucleotides and thermal stability of the resulting DNA duplexes was studied using UV-vis denaturing experiments and CD spectroscopy. The results indicate that the partially modified hydrophobic DNA can still retain B-conformation, although with lower thermal stability. On the other hand, the hypermodified ONs containing all four modified nucleotides did not hybridize to duplexes likely due to formation of aggregates as indicated by dynamic light scattering measurement. This work expands the toolkit of chemically modified nucleotides for applications in functional nucleic acids or nucleic acid therapeutics, but also shows the scope and limitations of the use of hydrophobic nucleotides in hypermodified oligonucleotides and DNA.

Identifiers

PMID41367679
PMCPMC12683653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.